Ligand captures another Captisol partner in melphalan deal with Spectrum
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals earned a $3 million license fee and may receive more than $50 million in milestone payments plus double-digit royalties from Spectrum Pharmaceuticals for its Captisol-enabled melphalan - giving Ligand more than a dozen partnered programs for technology that the San Diego-based company acquired just two years ago.